Castle Hook Partners LP purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,085,008 shares of the company’s stock, valued at approximately $38,062,000. Castle Hook Partners LP owned about 0.96% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after acquiring an additional 241,818 shares during the last quarter. Capital World Investors lifted its stake in shares of NewAmsterdam Pharma by 1.6% during the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after acquiring an additional 161,289 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its stake in shares of NewAmsterdam Pharma by 15.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after acquiring an additional 393,855 shares during the last quarter. 89.89% of the stock is owned by institutional investors.
Insider Activity
In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.74% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Stock Down 0.1%
NAMS opened at $30.15 on Thursday. The stock’s fifty day moving average is $33.26 and its two-hundred day moving average is $33.42. The company has a market capitalization of $3.52 billion, a P/E ratio of -16.84 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52 week low of $17.63 and a 52 week high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. Equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
